Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.

Dosentrx Ltd.1,000 enrolled

Overview

The goal of this observational study is to evaluate the safety, efficacy and patient satisfaction with the ReX Remote Digital Nurse by patients receiving solid oral medication. The study will evaluate and monitor use of ReX in respect of: * treatment duration * adverse events * patient adherence and compliance * engagement with ReX via patient-reported outcomes Patients participating in the study will receive their normal medication as standard of care via ReX. Progress will be monitored via patients' responses to questions presented on the ReX touch screen.

The ReX platform is a class 1 FDA device listed under product code NXB Dispenser Solid Medication. It comprises: * Hand-held medication dispenser with touch screen (ReX Remote Digital Nurse). * Disposable cartridge pre-loaded with pills or capsules. The cartridge includes an integral mouthpiece. Patients inhale at the mouthpiece causing pills to be dispensed into the mouth. * Web application (ReX Treatment Manager) which collects data generated by the ReX hand-held dispenser. ReX manages and monitors medication-based therapy by means of: * Reminders to take pills. Reminders are sent to patients and caregivers by email, SMS or via the telephone support team. * Electronic patient recorded outcomes (ePROs) presented to patients via the dispenser touch screen. ePROs include questions, tips and reminders. * Notifications sent by email or SMS in the event of the patient exceeding a pre-defined threshold. In this study, following training, patients will be offered their standard oral medication via the ReX Remote Digital Nurse. They will receive cartridges pre-loaded with medication by the pharmacy. Safety, efficacy and patient satisfaction with the device are monitored over a 24-week period by phone calls and periodic questionnaires. Data collected by the ReX Remote Digital Nurse include: * medication name * prescribed dosage * doses taken per day * pills taken per dose * ePRO responses * missed pill intakes

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Any Solid Oral Medication

Interventions

Use of ReX to dispense and monitor solid oral medication therapy.DEVICE

ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. 18 years of age or older. 2. Care team recommends the use of ReX as a standard of care. 3. Patients have 5th grade reading level. 4. Patient was prescribed oral medication. 5. Patient takes medication at home. Exclusion Criteria: 1. Patient has significant physical disability including poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent or use the ReX dispensing unit effectively. 2. Patient failed to pass the learning module during ReX onboarding flow. 3. Patient is at end stage or terminal illness with anticipated life expectancy of 6 months or less.

Locations (1)

OHC

Cincinnati, Ohio, United States

RECRUITING

Outcomes

Primary Outcomes

Treatment duration

At least 3 months while using ReX

Time frame: 24 weeks

Patient satisfaction

At least 3.5 on a scale up to 5

Time frame: 24 weeks

Adverse events

None related to use of ReX

Time frame: 24 weeks

Patient adherence

No. of pills taken by patient as a percentage of pills prescribed \>80%

Time frame: 24 weeks

Patient compliance

No. of pills taken as percentage of pills to be taken in alloted time frame \>70%

Time frame: 24 weeks

Patient engagement

No. of questions answered as a percentage of questions asked \>70% of ePROs

Time frame: 24 weeks

Central Contacts

Natan Paz

CONTACT

+972 52 6577126 natan.p@dosentrx.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.